[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100530236":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":69,"collaborators":72,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":20,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":20,"enrollmentInfo":83,"targetDuration":20,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":38,"whyStopped":20,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"ILN Cohort","Patients with LR3 observations would undergo CEUS and AMRI every 6 months; patients with LR4 observations would undergo CEUS and AMRI 3 months after enrollment and every 6 months thereafter. CEUS and AMRI will preferably be done the same day to minimize burden on the patient, although will be permitted to be completed within 14 days of each other. This interval is sufficiently short to minimize the chance of intervening events. AMRI and CEUS will be performed every 3-6 months until HCC development, regression to LR-1 or LR-2 (i.e., definitely or likely benign, respectively), or end of follow-up at 24 months post-enrollment.",[12,13],"Diagnostic Test: CEUS imaging","Diagnostic Test: aMRI imaging",[15,21],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","CEUS imaging","Contrast-enhanced ultrasound (CEUS)",[9],null,{"type":16,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"aMRI imaging","contrast enhanced abbreviated MRI (AMRI)",[9],[26,31],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Lisa Quirk, MS\u002FMPH","CONTACT","214-645-6179","lisa.quirk@utsouthwestern.edu",{"name":32,"role":28,"phone":33,"phoneExt":20,"email":34},"Sneha Deodhar, MS","214-645-1378","sneha.deodhar@utsouthwestern.edu",[36,54],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"University of Michigan","RECRUITING","Ann Arbor","Michigan","48109","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-83.74088,42.27756,{"lat":48,"lon":47},[51],{"name":52,"role":28,"phone":20,"phoneExt":20,"email":53},"Matthew DeMaio","demaioma@med.umich.edu",{"facility":5,"status":38,"city":55,"state":56,"zip":57,"country":42,"countryCode":43,"cosmosGeoPoint":58,"geoPoint":62,"contacts":63},"Dallas","Texas","75390",{"type":45,"coordinates":59},[60,61],-96.80667,32.78306,{"lat":61,"lon":60},[64,65,66],{"name":27,"role":28,"phone":20,"phoneExt":20,"email":30},{"name":32,"role":28,"phone":20,"phoneExt":20,"email":34},{"name":67,"role":68,"phone":20,"phoneExt":20,"email":20},"Amit Singal, MD","PRINCIPAL_INVESTIGATOR",{"type":68,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Amit Singal","Lead Principal Investigator",[73],{"name":37,"class":6},"100530236","ceus-vs-amri-for-hcc-detection-in-patients-with-indeterminate-liver-nodules-100530236",false,"NCT06184152","CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules","Contrast Ultrasound vs. Abbreviated MRI for Detection of HCC in Patients With Indeterminate Liver Nodules","Inclusion Criteria:\n\n* Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.\n* Adults 18 years old and above\n\nExclusion Criteria:\n\n* Patients post liver transplantation\n* Patients with concurrent or prior HCC (LR-5 or biopsy proven)\n* other liver cancer including cholangiocarcinoma\n* Patients with any active extra-hepatic malignancy\n* Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit\n* Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia","ALL","18 Years",{"count":84,"type":85},600,"ESTIMATED","INTERVENTIONAL",[88],"NA","The study will be conducted at the following locations:\n\n1. UT Southwestern Medical Center\n2. Parkland Health and Hospital System\n3. University of Michigan\n\nInvestigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound for early-stage HCC detection in patients with indeterminate liver nodules.",[91,92],"HCC","Hepatocellular Carcinoma",[94,95,96],"LR3","LR4","HCC Surveillance","2026-06-30",{"date":99,"type":100},"2026-07-02","ACTUAL",{"date":102,"type":100},"2023-11-28",{"date":104,"type":85},"2028-11-28",{"name":5,"class":6},2]